Lenvatinib mesylate

Lenvatinib mesylate is a methanesulfonate salt obtained by reaction of lenvatinib with one molar equivalent of methanesulfonic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine. Among its listed roles, it functions as a EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast growth factor receptor antagonist, an orphan drug, a vascular endothelial growth factor receptor antagonist and an antineoplastic agent. It includes a lenvatinib(1+). It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors, Tyrosine Kinase Inhibitors and VEGF inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lenvatinib Methanesulfonate and Lenvima. Its PubChem CID is 11237762.